{"disease":{"id":"non-small-cell-lung-cancer-nsclc-with-nonprogression-following-4-cycles-of-platinum-based-chemotherapy","name":"non small cell lung cancer nsclc with nonprogression following 4 cycles of platinum based chemotherapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01186861","title":"Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":205,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}